Eman A Toraih1, Manal S Fawzy2, Eman A Mohammed1, Mohammad H Hussein3,4, Mohamad M El-Labban5. 1. Department of Histology and Cell Biology (Genetics Unit), Faculty of Medicine, Suez Canal University, Ismailia, Egypt. 2. Department of Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. manal2_khashana@ymail.com. 3. Pulmonologist, Ministry of Health, Cairo, Egypt. 4. Emergency Department, Al Jahra Hospital, Al Jahra, Kuwait. 5. Department of Pathology, Faculty of Medicine, Port Said University, Port Said, Egypt.
Abstract
INTRODUCTION: MicroRNAs (miRNAs) have been linked to cancer development and progression. The molecular mechanisms underlying the genetic associations of the miRNA single nucleotide polymorphism with cancer vary by cancer site. As there are no previous studies on the miR-196a2 variant or expression in any type of cancer among our population, we aimed to determine the expression profile of mature miR-196a2 in various types of solid tumors and to analyze the impact of its polymorphism (rs11614913; C/T) on the expression levels. MATERIALS AND METHODS: The study included 230 cancer patients (including 17 types of cancer), 26 patients with pre-cancer lesions, and 100 unrelated controls. Archived formalin-fixed, paraffin-embedded specimens (n = 197) were available for both miRNA expression analysis and single nucleotide polymorphism identification. Venous blood was collected from 59 histologically confirmed sporadic cancer patients and the study controls for single nucleotide polymorphism identification. Real-time polymerase chain reaction analysis was performed for allelic discrimination and relative quantification of miR-196a2 in the study samples. In silico target gene prediction and network analysis was performed. RESULTS: We found that individuals with the T variant were associated with cancer risk under all genetic association models, especially in colorectal, esophageal, skin, lung, thyroid, and renal cancer. Overall and stratified analysis showed miR-196a2 over-expression in most of the current malignant tumor samples relative to their corresponding cancer-free tissues. Carriers of the C allele had significantly higher expression levels of miR-196a2. Correlation with the clinicopathological features of cancer showed organ-specific effects. Gene enrichment analysis of predicted and validated targets speculated the putative role of miR-196a2 in cancer-associated biology. CONCLUSIONS: We highlighted cancer-type specific expression profiles of miR-196a2, which was correlated with the clinicopathological features in various types of cancer. Taken together, our results suggest that the miRNA signature could have promising diagnostic and prognostic significance.
INTRODUCTION: MicroRNAs (miRNAs) have been linked to cancer development and progression. The molecular mechanisms underlying the genetic associations of the miRNA single nucleotide polymorphism with cancer vary by cancer site. As there are no previous studies on the miR-196a2 variant or expression in any type of cancer among our population, we aimed to determine the expression profile of mature miR-196a2 in various types of solid tumors and to analyze the impact of its polymorphism (rs11614913; C/T) on the expression levels. MATERIALS AND METHODS: The study included 230 cancerpatients (including 17 types of cancer), 26 patients with pre-cancer lesions, and 100 unrelated controls. Archived formalin-fixed, paraffin-embedded specimens (n = 197) were available for both miRNA expression analysis and single nucleotide polymorphism identification. Venous blood was collected from 59 histologically confirmed sporadic cancerpatients and the study controls for single nucleotide polymorphism identification. Real-time polymerase chain reaction analysis was performed for allelic discrimination and relative quantification of miR-196a2 in the study samples. In silico target gene prediction and network analysis was performed. RESULTS: We found that individuals with the T variant were associated with cancer risk under all genetic association models, especially in colorectal, esophageal, skin, lung, thyroid, and renal cancer. Overall and stratified analysis showed miR-196a2 over-expression in most of the current malignant tumor samples relative to their corresponding cancer-free tissues. Carriers of the C allele had significantly higher expression levels of miR-196a2. Correlation with the clinicopathological features of cancer showed organ-specific effects. Gene enrichment analysis of predicted and validated targets speculated the putative role of miR-196a2 in cancer-associated biology. CONCLUSIONS: We highlighted cancer-type specific expression profiles of miR-196a2, which was correlated with the clinicopathological features in various types of cancer. Taken together, our results suggest that the miRNA signature could have promising diagnostic and prognostic significance.
Authors: Katalin Gocze; Katalin Gombos; Krisztina Juhasz; Krisztina Kovacs; Bela Kajtar; Marta Benczik; Peter Gocze; Balazs Patczai; Istvan Arany; Istvan Ember Journal: Anticancer Res Date: 2013-06 Impact factor: 2.480
Authors: Manal S Fawzy; Dahlia I Badran; Essam Al Ageeli; Saeed Awad M Al-Qahtani; Saleh Ali Alghamdi; Ghada M Helal; Eman A Toraih Journal: Oxid Med Cell Longev Date: 2018-03-21 Impact factor: 6.543
Authors: Manal S Fawzy; Eman A Toraih; Afaf Ibrahiem; Hala Abdeldayem; Amany O Mohamed; Mohamed M Abdel-Daim Journal: PLoS One Date: 2017-11-01 Impact factor: 3.240
Authors: Eman A Toraih; Afaf T Ibrahiem; Manal S Fawzy; Mohammad H Hussein; Saeed Awad M Al-Qahtani; Aly A M Shaalan Journal: Oxid Med Cell Longev Date: 2017-09-20 Impact factor: 6.543
Authors: Eman A Toraih; Saleh Ali Alghamdi; Aya El-Wazir; Marwa M Hosny; Mohammad H Hussein; Moataz S Khashana; Manal S Fawzy Journal: PLoS One Date: 2018-10-05 Impact factor: 3.240